Trial Profile
A TWO-PART, RANDOMIZED PHASE III, DOUBLE-BLIND, MULTICENTER TRIAL ASSESSING THE EFFICACY AND SAFETY OF PERTUZUMAB IN COMBINATION WITH STANDARD CHEMOTHERAPY VS. PLACEBO PLUS STANDARD CHEMOTHERAPY IN WOMEN WITH RECURRENT PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER AND LOW HER3 mRNA EXPRESSION
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pertuzumab (Primary) ; Gemcitabine; Paclitaxel; Topotecan
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PENELOPE
- Sponsors Roche
- 05 Jul 2016 Status changed from active, no longer recruiting to completed.
- 05 Jul 2016 Time frame for primary endpoint has been changed; a treatment arm has been added.
- 06 Jun 2016 Results published in the Journal of Clinical Oncology